Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie.
Hosted on MSN29d
AbbVie acquires Nimble Therapeutics to boost R&DAbbVie (NYSE: NYSE:ABBV), a global biopharmaceutical ... has announced the completion of its acquisition of Nimble Therapeutics, a move aimed at strengthening its research and development pipeline ...
8d
24/7 Wall St. on MSNAbbVie Just Paid Investors: Here's How Much They ReceivedAbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50 ...
AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a preclinical-stage, oral drug for psoriasis. US-based Nimble was set up in ...
Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion in milestone payments. AbbVie and Neomorph have announced a collaboration ...
In a separate development, AbbVie has completed the acquisition of Nimble Therapeutics, which is now integrated into AbbVie's operations. The oral peptide interleukin 23 receptor (IL23R ...
AbbVie ABBV announced that it has entered ... Earlier this week, ABBV completed the acquisition of immunology drugmaker Nimble Therapeutics. With this acquisition, it added Nimble’s innovative ...
Dividend-growth stocks offer steady income and long-term value. With the Fed holding rates and inflation expected to ease, ...
AbbVie has also just completed its previously announced $200m acquisition of Nimble Therapeutics, marking a notable boost to its immunology pipeline. The agreement includes Nimble’s lead asset, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results